Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.

American journal of respiratory and critical care medicine·2026

Same author

Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.

Infection·2026

Same author

Diagnostic discordance and differential diagnoses of community-acquired pneumonia in the emergency department.

BMC emergency medicine·2026

Same author

Association of German Bronchiectasis Registry participation with disease course.

ERJ open research·2026

Same author

Adolescent wellbeing after COVID-related school-closings.

Frontiers in psychology·2026

Same author

Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.

Respiration; international review of thoracic diseases·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Current and new vaccines against pneumococci].

Jessica Rademacher¹

¹Klinik für Pneumologie und Infektiologie, Medizinische Hochschule Hannover (MHH), OE 6870, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. rademacher.jessica@mh-hannover.de.

Innere Medizin (Heidelberg, Germany)

|September 2, 2024

Summary

Pneumococcal conjugate vaccine 20 (PCV20) offers broader protection against Streptococcus pneumoniae infections than PCV13. Updated German recommendations simplify vaccination strategies for adults, enhancing public health protection.

Keywords:

Streptococcus pneumoniae Pneumococcal infections/morbidity Pneumococcal infections/mortality Pneumococcal vaccines/serotype coverage Vaccines, conjugate

More Related Videos

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Experiment Videos

Last Updated: Jun 14, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Area of Science:

Immunology
Infectious Diseases
Public Health

Context:

Streptococcus pneumoniae causes serious respiratory and invasive infections, including pneumonia, meningitis, and bacteremia.
Pneumococcal pneumonia significantly increases morbidity and mortality, especially in individuals with chronic obstructive pulmonary disease (COPD).
The 13-valent pneumococcal conjugate vaccine (PCV13) reduced disease burden, but non-PCV13 serotypes remain a concern.

Purpose:

To evaluate the efficacy and immune response of the 20-valent pneumococcal conjugate vaccine (PCV20).
To highlight the updated recommendations for PCV20 use in adults by the German Standing Committee on Vaccination (STIKO).
To discuss the evolving landscape of pneumococcal vaccines and strategies for disease prevention.

Summary:

PCV20 provides extended serotype coverage compared to PCV13, addressing infections caused by currently circulating serotypes.
Clinical trials demonstrate a robust immune response to PCV20.
Updated STIKO recommendations endorse PCV20 for all adult vaccination indications, simplifying and enhancing the vaccination strategy.

Impact:

PCV20 represents a significant advancement in preventing pneumococcal diseases.
Simplified vaccination schedules and broader coverage are expected to improve public health outcomes.
Future vaccine developments aim for even wider serotype coverage and enhanced immunological properties to further decrease pneumococcal disease burden.